Handelsbanken Fonder AB reduced its position in The Clorox Company (NYSE:CLX - Free Report) by 19.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,162 shares of the company's stock after selling 16,852 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.06% of Clorox worth $11,557,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of CLX. Wealth Group Ltd. acquired a new position in Clorox in the 3rd quarter valued at about $231,000. Blue Trust Inc. grew its position in Clorox by 34.7% in the 3rd quarter. Blue Trust Inc. now owns 913 shares of the company's stock valued at $149,000 after acquiring an additional 235 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Clorox by 2.5% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 4,228 shares of the company's stock valued at $689,000 after acquiring an additional 102 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in Clorox in the 3rd quarter valued at about $395,000. Finally, Dakota Wealth Management grew its position in Clorox by 15.4% in the 3rd quarter. Dakota Wealth Management now owns 13,739 shares of the company's stock valued at $2,238,000 after acquiring an additional 1,829 shares in the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have weighed in on the company. Barclays lifted their target price on Clorox from $130.00 to $140.00 and gave the company an "underweight" rating in a research report on Wednesday, February 5th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $150.00 price objective on shares of Clorox in a research note on Thursday, January 30th. Evercore ISI lifted their price objective on Clorox from $145.00 to $155.00 in a research note on Tuesday, February 4th. DA Davidson decreased their price objective on Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Finally, TD Cowen upgraded Clorox from a "sell" rating to a "hold" rating and lifted their price objective for the company from $155.00 to $170.00 in a research note on Wednesday, November 6th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $158.21.
View Our Latest Stock Report on Clorox
CLX stock opened at $157.41 on Friday. The business has a 50 day moving average price of $157.72 and a 200 day moving average price of $159.73. The stock has a market cap of $19.39 billion, a price-to-earnings ratio of 43.01, a PEG ratio of 2.62 and a beta of 0.42. The Clorox Company has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52.
Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.39 by $0.16. Clorox had a return on equity of 316.87% and a net margin of 6.38%. During the same quarter last year, the business earned $2.16 EPS. Equities research analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.